Unveiling the Notable Consequences in the Management of Anxiety Disorder
Abstract
Anxiety disorders, encompassing generalized anxiety disorder, social anxiety, panic disorder, and specific phobias, are pervasive mental health conditions associated with significant distress and functional impairment. A comprehensive search was conducted from July 2024 to December 2025 across PubMed, Scopus, and Embase from inception to the present. According to the document on metabolomic markers in disorders of anxiety, these disorders arise from a complex interaction of genetic, neurobiological, and psychosocial factors. Key challenges in managing anxiety disorders include accurate diagnosis and distinguishing anxiety symptoms from overlapping medical conditions such as asthma, atrial fibrillation, and hyperthyroidism. The present investigation is narrative review. It provides an informative, valuable narrative review of the history, abnormalities, and roles of neurotransmitters—norepinephrine, serotonin, dopamine, and GABA—and the involvement of brain structures such as the amygdala and limbic system, which underscore the neurobiological basis of anxiety. Current treatments concentrate on a combination of Selective serotonin reuptake Inhibitors (SSRIs), serotonin-nor-epinephrine reuptake Inhibitors (SNRIs), and benzodiazepines, alongside cognitive behavioural remedy (CBT). However, these approaches are not universally effective, and issues such as drug dependency and side effects remain critical obstacles. Emerging research in metabolomics offers potential for identifying biomarkers that could improve diagnostic accuracy and treatment personalization. Integrating metabolomic insights with traditional and complementary therapies may enhance treatment outcomes. Addressing these multifaceted challenges requires interdisciplinary collaboration to advance research and develop tailored, effective strategies for managing anxiety disorders in diverse patient populations.
Keywords: Anxiety, Anxiety disorders, Metabolomic markers, Biomarkers
Keywords:
Anxiety, Anxiety disorders, Metabolomic markers, BiomarkersDOI
https://doi.org/10.22270/jddt.v16i3.7631References
1. Craske MG, Rauch SL, Ursano R, Prenoveau J, Pine DS, Zinbarg RE. What is an anxiety disorder?. Focus. 2011 Jul;9(3):369-88. https://doi.org/10.1176/foc.9.3.foc369
2. Aragon A, Kings J, Playford ED. The role of occupational therapy in the rehabilitation of people with movement disorders. Rehabilitation in Movement Disorders. 2013 May 23:69. https://doi.org/10.1017/CBO9781139012942.008
3. Gentes EL, Ruscio AM. A meta-analysis of the relation of intolerance of uncertainty to symptoms of generalized anxiety disorder, major depressive disorder, and obsessive–compulsive disorder. Clinical psychology review. 2011 Aug 1;31(6):923-33. https://doi.org/10.1016/j.cpr.2011.05.001
4. Martin P. The epidemiology of anxiety disorders: a review. Dialogues in clinical neuroscience. 2003 Sep 30;5(3):281-98. https://doi.org/10.31887/dcns.2003.5.3/pmartin
5. Madonna D, Delvecchio G, Soares JC, Brambilla P. Structural and functional neuroimaging studies in generalized anxiety disorder: a systematic review. Brazilian Journal of Psychiatry. 2019 May 16;41:336-62. https://doi.org/10.1590/1516-4446-2018-0108
6. Ustinova Y, Cardeña E. Combat stress disorders and their treatment in ancient Greece. Psychological trauma: Theory, research, practice, and policy. 2014 Nov;6(6):739. https://psycnet.apa.org/doi/10.1037/a0036461
7. Agyapong B, Shalaby R, Hay K, Pattison R, Eboreime E, Korthuis M, Wei Y, Agyapong VI. Exploring sociodemographic characteristics, adverse childhood experience, and mental health history as predictors of anxiety and depression among adolescents and young adults: findings from the MoreGoodDays support program in Alberta, Canada. Behavioral Sciences. 2023 Sep 8;13(9):749. https://doi.org/10.3390/bs13090749
8. Rosqvist J. Exposure treatments for anxiety disorders: A practitioner's guide to concepts, methods, and evidence-based practice. Routledge; 2012 Oct 12. https://doi.org/10.4324/9780203843833
9. Lazarus RS. Cognition and motivation in emotion. American psychologist. 1991 Apr;46(4):352. https://psycnet.apa.org/doi/10.1037/0003-066X.46.4.352
10. Sitzman K, Watson J. Caring science, mindful practice: Implementing Watson’s human caring theory. Springer Publishing Company; 2018 Apr 28. http://dx.doi.org/10.1177/0894318414534468
11. Baldessarini RJ. Drug therapy of depression and anxiety disorders. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Edited by Brunton LL, Lazo JS, Parker KL. New York, McGraw-Hill. 2006:429-60.
12. Leahy RL, Holland SJ, McGinn LK. Treatment plans and interventions for depression and anxiety disorders. Guilford press; 2011 Oct 26.
13. Kantorovich V, Pacak K. Pheochromocytoma and paraganglioma. Progress in brain research. 2010 Jan 1;182:343-73. https://doi.org/10.1016/s0079-6123(10)82015-1
14. Alguire C, Chbat J, Forest I, Godbout A, Bourdeau I. Unusual presentation of pheochromocytoma: thirteen years of anxiety requiring psychiatric treatment. Endocrinology, Diabetes & Metabolism Case Reports. 2018 Apr 6;2018(1). https://doi.org/10.1530/edm-17-0176
15. Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F. Pheochromocytoma: an update on genetics and management. Endocrine-related cancer. 2007 Dec 1;14(4):935-56. https://doi.org/10.1677/erc-07-0142
16. Lehrer P, Feldman J, Giardino N, Song HS, Schmaling K. Psychological aspects of asthma. Journal of consulting and clinical psychology. 2002 Jun;70(3):691. https://doi.org/10.1037//0022-006x.70.3.691
17. Ten Thoren C, Petermann F. Reviewing asthma and anxiety. Respiratory medicine. 2000 May 1;94(5):409-15. https://doi.org/10.1053/rmed.1999.0757
18. Deshmukh VM, Toelle BG, Usherwood T, O’Grady B, Jenkins CR. Anxiety, panic and adult asthma: A cognitive-behavioral perspective. Respiratory medicine. 2007 Feb 1;101(2):194-202. https://doi.org/10.1016/j.rmed.2006.05.005
19. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. Journal of asthma and allergy. 2017 Mar 7:47-56. https://doi.org/10.2147/jaa.s121276
20. Polloni L, Muraro A. Anxiety and food allergy: a review of the last two decades. Clinical & Experimental Allergy. 2020 Apr;50(4):420-41. https://doi.org/10.1111/cea.13548
21. Hsieh MT, Liang SH, Yang YH, Kuo TY, Lin TY, Wang TN, Chen VC, Wu MH. Allergic rhinitis increases the risk of incident panic disorder among young individuals: a nationwide population-based cohort study in Taiwan. Journal of affective disorders. 2019 Jun 1;252:60-7. https://doi.org/10.1016/j.jad.2019.04.037
22. Stauder, A. and Kovács, M., 2003. Anxiety symptoms in allergic patients: identification and risk factors. Biopsychosocial Science and Medicine, 65(5), pp.816-823. https://doi.org/ 10.1097/01.PSY.0000088620.66211.B1
23. Lehrer P, Feldman J, Giardino N, Song HS, Schmaling K. Psychological aspects of asthma. Journal of consulting and clinical psychology. 2002 Jun;70(3):691. https://doi.org/10.1037//0022-006x.70.3.691
24. Lehrer PM, Isenberg S, Hochron SM. Asthma and emotion: a review. Journal of Asthma. 1993 Jan 1;30(1):5-21. https://doi.org/10.3109/02770909309066375
25. Clark D. Herbal Healing for Children: A Parent's Guide to Treatments for Common Childhood Illnesses. Book Publishing Company; 2011 Apr 5.
26. Mahler DA. Breathe Easy: Relieving the Symptoms of Chronic Lung Disease. University Press of New England; 2017 Jun 6.
27. Ye Q, He XO, D’Urzo A. A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulmonary Therapy. 2017 Jun; 3:1-8. https://doi.org/10.1007/s41030-017-0043-5
28. Rosenberg M. Born with a Junk Food Deficiency: How Flaks, Quacks, and Hacks Pimp the Public Health. Prometheus Books; 2012 Apr 10.
29. Alangari AA. Corticosteroids in the treatment of acute asthma. Annals of thoracic medicine. 2014 Oct 1;9(4):187-92. https://doi.org/10.4103/1817-1737.140120
30. Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG. Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. Multidisciplinary Respiratory Medicine. 2019 Dec;14:1-8. https://doi.org/10.1186/s40248-019-0189-0
31. Nanda A, Russell AF, Bingemann TA. Pharmacology update: emergency and controller medications for treatment of asthma. NASN School Nurse. 2022 Jan;37(1):31-5. https://doi.org/10.1177/1942602x211036933
32. Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M. Severe asthma and biological therapy: when, which, and for whom. Pulmonary therapy. 2020 Jun;6:47-66. https://doi.org/10.1007/s41030-019-00109-1
33. Lévy S, Steinbeck G, Santini L, Nabauer M, Maceda DP, Kantharia BK, Saksena S, Cappato R. Management of atrial fibrillation: Two decades of progress—A scientific statement from the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology. 2022 Oct;65(1):287-326. https://doi.org/10.1007/s10840-022-01195-z
34. Ahmed M. Chronic cardiac diseases and patients’ mental health: Exploring the impact of improving mental health on chronic heart failure prognosis and adherence to treatment behaviour in primary care based patients.
35. Cousineau JP, Dawe AM, Alpaugh M. Investigating the Interplay between Cardiovascular and Neurodegenerative Disease. Biology. 2024 Sep 26;13(10):764. https://doi.org/10.3390/biology13100764
36. Wang Z, Yang B. Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. InPolypharmacology: Principles and Methodologies 2022 Aug 2 (pp. 133-198). Cham: Springer International Publishing. http://dx.doi.org/10.1007/978-3-031-04998-9_4
37. Caldentey G, Khairy P, Roy D, Leduc H, Talajic M, Racine N, White M, O'Meara E, Guertin MC, Rouleau JL, Ducharme A. Prognostic value of the physical examination in patients with heart failure and atrial fibrillation: insights from the AF-CHF trial (atrial fibrillation and chronic heart failure). JACC: Heart Failure. 2014 Feb;2(1):15-23. https://doi.org/10.1016/j.jchf.2013.10.004
38. Haemers P, Claus P, Willems R. The use of cardiac magnetic resonance imaging in the diagnostic workup and treatment of atrial fibrillation. Cardiology research and practice. 2012;2012(1):658937. https://doi.org/10.1155/2012/658937
39. Bonnesen MP, Frodi DM, Haugan KJ, Kronborg C, Graff C, Højberg S, Køber L, Krieger D, Brandes A, Svendsen JH, Diederichsen SZ. Day-to-day measurement of physical activity and risk of atrial fibrillation. European heart journal. 2021 Oct 7;42(38):3979-88. https://doi.org/10.1093/eurheartj/ehab597
40. Mittal T. Pacemakers—A journey through the years. Indian Journal of Thoracic and Cardiovascular Surgery. 2005 Sep;21:236-49. https://doi.org/10.1007/s12055-005-0060-0
41. Czick ME, Shapter CL, Silverman DI. Atrial fibrillation: the science behind its defiance. Aging and disease. 2016 Oct 1;7(5):635. https://doi.org/10.14336/AD.2016.0211
42. Cannon CP, Vierck E. The New Heart Disease Handbook: Everything You Need to Know to Effectively Reverse and Manage Heart Disease. Fair Winds Press; 2009 Sep 1.
43. Regazzoli D, Ancona F, Trevisi N, Guarracini F, Radinovic A, Oppizzi M, Agricola E, Marzi A, Sora NC, Della Bella P, Mazzone P. Left atrial appendage: physiology, pathology, and role as a therapeutic target. BioMed research international. 2015;2015(1):205013. https://doi.org/10.1155/2015/205013
44. Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease–double trouble. Advances in medical sciences. 2018 Mar 1;63(1):30-5. https://doi.org/10.1016/j.advms.2017.06.005
45. Simon NM, Blacker D, Korbly NB, Sharma SG, Worthington JJ, Otto MW, Pollack MH. Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. Journal of affective disorders. 2002 May 1;69(1-3):209-17. https://doi.org/10.1016/s0165-0327(01)00378-0
46. Shoib S, Ahmad J, Wani MA, Ullah I, Tarfarosh SF, Masoodi SR, Ramalho R. Depression and anxiety among hyperthyroid female patients and impact of treatment. Middle East Current Psychiatry. 2021 Jun 8;28(1):26. https://doi.org/10.1186/s43045-021-00107-7
47. Salman AG, Mahdi IA, Mukhlef AK, abdalsattar Mohammad R, Zaghir MS, muatezWadaa'a N. Physiological aspects of thyroid disorders: Anatomy, hormones, diagnosis and management. Current Clinical and Medical Education. 2024 May 2;2(5):17-32.
48. Fountoulakis KN, Iacovides A, Grammaticos P, St Kaprinis G, Bech P. Thyroid function in clinical subtypes of major depression: an exploratory study. BMC psychiatry. 2004 Dec;4:1-9. https://doi.org/10.1186/1471-244X-4-6
49. Askari E, Saidi B, Evangelista L. Indications for diagnostic whole-body iodine scan: a review of guidelines. Nuclear Medicine Communications. 2024 Dec 1;45(12):998-1006. https://doi.org/10.1097/MNM.0000000000001906
50. Stohn JP, Martinez ME, Hernandez A. Decreased anxiety-and depression-like behaviors and hyperactivity in a type 3 deiodinase-deficient mouse showing brain thyrotoxicosis and peripheral hypothyroidism. Psychoneuroendocrinology. 2016 Dec 1;74:46-56. https://doi.org/10.1016/j.psyneuen.2016.08.021
51. Holtorf K. Peripheral thyroid hormone conversion and its impact on TSH and metabolic activity. Journal of Restorative medicine. 2014 Apr 1;3(1):30. http://dx.doi.org/10.14200/jrm.2014.3.0103
52. Lee SY, Pearce EN. Hyperthyroidism: a review. Jama. 2023 Oct 17;330(15):1472-83. https://doi.org/10.1001/jama.2023.19052
53. Kaplan MM, Meier DA, Dworkin HJ. Treatment of hyperthyroidism with radioactive iodine. Endocrinology and metabolism clinics of North America. 1998 Mar 1;27(1):205-23. https://doi.org/10.1016/s0889-8529(05)70307-8
54. Lee SY, Pearce EN. Hyperthyroidism: a review. Jama. 2023 Oct 17;330(15):1472-83.
55. Rehm J. The risks associated with alcohol use and alcoholism. Alcohol Research & Health. 2011;34(2):135.
56. Schuckit MA, Hesselbrock V. Alcohol dependence and anxiety disorders: what is the relationship?. Focus. 1994 Jul;151(3):1723-453. https://doi.org/10.1176/ajp.151.12.1723
57. Chambless DL, Cherney J, Caputo GC, Rheinstein BJ. Anxiety disorders and alcoholism:: A study with inpatient alcoholics. Journal of Anxiety Disorders. 1987 Jan 1;1(1):29-40.
58. Clark DB, Sayette MA. Anxiety and the development of alcoholism: Clinical and scientific issues. American Journal on Addictions. 1993 Jan 1;2(1):59-76. https://doi.org/10.1111/j.1521-0391.1993.tb00371.x
59. Johnson BA. Medication treatment of different types of alcoholism. American Journal of Psychiatry. 2010 Jun 1;167(6):630-9. https://doi.org/10.1176/appi.ajp.2010.08101500
60. Paulino PJ, Cuthrell KM, Tzenios N. Non Alcoholic Fatty Liver Disease; Disease Burden, Management, and Future Perspectives. International Research Journal of Gastroenterology and Hepatology. 2024 Jan 4;7(1):1-3.
61. LaBarre C, Bradizza CM, Linn BK, Zhao J, Knapp KS, Wilding GE, Stasiewicz PR. Predictors of National Institute on Alcohol Abuse and Alcoholism (NIAAA) alcohol recovery among individuals in alcohol treatment: Implications for social work. Social Work Research. 2024 Sep;48(3):201-11. https://doi.org/10.1093/swr/svae012
62. Epel ES, Crosswell AD, Mayer SE, Prather AA, Slavich GM, Puterman E, Mendes WB. More than a feeling: A unified view of stress measurement for population science. Frontiers in neuroendocrinology. 2018 Apr 1;49:146-69. https://doi.org/10.1016/j.yfrne.2018.03.001
63. Watson D. Intraindividual and interindividual analyses of positive and negative affect: their relation to health complaints, perceived stress, and daily activities. Journal of personality and social psychology. 1988 Jun;54(6):1020. https://doi.org/10.1037//0022-3514.54.6.1020
64. Attar ET. Review of electroencephalography signals approaches for mental stress assessment. Neurosciences Journal. 2022 Oct 1;27(4):209-15. https://doi.org/10.17712/nsj.2022.4.20220025
65. Electrophysiology TF. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation. 1996 Mar 1;93(5):1043-65. https://doi.org/10.1161/01.CIR.93.5.1043
66. Sharafeddin SF, Chehade Z, Sayed SE, Salloum D, Nahouli L, Hannoun A, Ghazeeri G. The effect of environmental stressors on anti-mullerian hormone levels in Lebanese women: a retrospective study. PLoS One. 2025 Nov 6;20(11):e0336016. https://doi.org/10.1371/journal.pone.0336016
67. Fonseca-Rodrigues D, Rodrigues A, Martins T, Pinto J, Amorim D, Almeida A, Pinto-Ribeiro F. Correlation between pain severity and levels of anxiety and depression in osteoarthritis patients: a systematic review and meta-analysis. Rheumatology. 2022 Jan 1;61(1):53-75. https://doi.org/10.1093/rheumatology/keab512
68. Lyu D, Qian R, Ge F, Wang Y, Wang H, Zhao Y, Han H, Liu R, Liu Y, Chen Y, Ji C. Exploring the associations between data-driven insomnia disorder combined with mild anxiety or/and depressive symptoms and the efficacy of Cognitive-Behavioral Therapy for insomnia. International Journal of Clinical and Health Psychology. 2025 Jan 1;25(1):100562. https://doi.org/10.1016/j.ijchp.2025.100562
69. Hüfner K, Rausch LK, Bichler CS, Burtscher J, Falla M, Weiss EM. The effect of aging at moderate altitude on cognition and symptoms of depression and anxiety. Gerontology. 2025 Oct 15;71(10):852-60. https://doi.org/10.1159/000547599
70. Miqdadi AI, Chan CM, Alhadidi M, Yoong TL, Hui KO. Assessing the level of panic symptoms, anxiety, and quality of life among people experiencing panic attacks. Journal of Psychosocial Nursing and Mental Health Services. 2025 Jun 1;63(6):39-48. https://doi.org/10.3928/02793695-20250217-05
71. AbuNaba'a Y, Basheti IA. Assessing the impact of medication management review service for females diagnosed with depression and anxiety: A randomized control trial. Journal of Evaluation in Clinical Practice. 2020 Oct;26(5):1478-89. https://doi.org/10.1111/jep.13314
72. Das KP, Gavade P. A review on the efficacy of artificial intelligence for managing anxiety disorders. Frontiers in Artificial Intelligence. 2024 Oct 16;7:1435895. https://doi.org/10.3389/frai.2024.1435895
73. Houglum JE, Harrelson GL, Seefeldt TM. Drugs for treating psychiatric disorders. In Principles of pharmacology for athletic trainers 2024 Jun 1 (pp. 236-267). Routledge.
74. Hendriks GJ, Janssen N, Robertson L, van Balkom AJ, van Zelst WH, Wolfe S, Oude Voshaar RC, Uphoff E. Cognitive behavioural therapy and third‐wave approaches for anxiety and related disorders in older people. Cochrane Database of Systematic Reviews. 2024(7). https://doi.org/10.1002/14651858.CD007674.pub3
75. Zhu Y, Jha SC, Shutta KH, Huang T, Balasubramanian R, Clish CB, Hankinson SE, Kubzansky LD. Psychological distress and metabolomic markers: A Systematic Review. MedRxiv. 2022 Feb 25:2022-02. https://doi.org/10.1101/2022.02.24.22271464
76. Sheffield Z, Paul P, Krishnakumar S, Pan D. Current strategies and future directions of wearable biosensors for measuring stress biochemical markers for neuropsychiatric applications. Advanced Science. 2025 Feb;12(5):2411339. https://doi.org/10.1002/advs.202411339
77. Kelaiditis CF, Gibson EL, Dyall SC. Effects of long-chain omega-3 polyunsaturated fatty acids on reducing anxiety and/or depression in adults; A systematic review and meta-analysis of randomised controlled trials. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2023 May 1;192:102572. https://doi.org/10.1016/j.plefa.2023.102572
Published
Abstract Display: 121 
PDF Downloads: 178 PDF Downloads: 35 How to Cite
Issue
Section
Copyright (c) 2026 Vandana Gupta , Noopur Srivastava
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.